PFI-1, a highly selective protein interaction inhibitor, targeting BET bromodomains.

Authors

Sarah Picaud, University of Oxford, Oxford, UK
David Da Costa, University of Birmingham
Angeliki Thanasopoulou, University of Basel
Panagis Filippakopoulos, University of Oxford, Oxford, UK
Paul V. Fish, Pfizer Worldwide Medicinal Chemistry
Martin Philpott, University of Oxford, Oxford, UK
Oleg Fedorov, University of Oxford, Oxford, UK
Paul Brennan, University of Oxford, Oxford, UK
Mark E. Bunnage, Pfizer Worldwide Medicinal Chemistry
Dafydd R. Owen, Pfizer Worldwide Medicinal Chemistry
James E. Bradner, Dana-Farber Cancer Institute, Boston, MA
Phillippe Taniere, Queen Elizabeth Medical Centre, Birmingham, United Kingdom
Brendan O'Sullivan, Queen Elizabeth Medical Centre, Birmingham, United Kingdom
Susanne Muller, University of Oxford, Oxford, UK
Juerg Schwaller, University of Basel
Tatjana Stankovic, University of Birmingham
Stefan Knapp, George Washington UniversityFollow

Document Type

Journal Article

Publication Date

6-1-2013

Journal

Cancer Research

Volume

Volume 73 Issue 11

Inclusive Pages

3336-3346

APA Citation

Picaud, S., Da Costa, D., Thanasopoulou, A., Filippakopoulos, P., Fish, P. V., Philpott, M., . . . Knapp, S. (2013). PFI-1, a highly selective protein interaction inhibitor, targeting BET bromodomains. Cancer Research, 73(11), 3336-3346.

Peer Reviewed

1